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BACKGROUND
We previously reported the results of a randomized, controlled trial showing that 
repeat doses of antenatal corticosteroids reduced the risk of respiratory distress 
syndrome and serious neonatal morbidity. However, data have not been available 
regarding longer-term effects of this treatment.
METHODS
Women who had received an initial course of corticosteroid treatment 7 or more days 
previously were randomly assigned to receive an intramuscular injection of cortico-
steroid (11.4 mg of betamethasone) or saline placebo; the dose was repeated weekly 
if the mother was still considered to be at risk for preterm delivery and the duration 
of gestation was less than 32 weeks. We assessed survival free of major neurosen-
sory disability and body size of the children at 2 years of corrected age.
RESULTS
Of the 1085 children who were alive at 2 years of age, 1047 (96.5%) were seen for 
assessment (521 exposed to repeat-corticosteroid treatment and 526 exposed to 
placebo). The rate of survival free of major disability was similar in the repeat-
corticosteroid and placebo groups (84.4% and 81.0%, respectively; adjusted relative 
risk, 1.04, 95% confidence interval, 0.98 to 1.10; adjusted P = 0.20). There were no 
significant differences between the groups in body size, blood pressure, use of health 
services, respiratory morbidity, or child behavior scores, although children exposed 
to repeat doses of corticosteroids were more likely than those exposed to placebo to 
warrant assessment for attention problems (P = 0.04).
CONCLUSIONS
Administration of repeat doses of antenatal corticosteroids reduces neonatal morbid-
ity without changing either survival free of major neurosensory disability or body 
size at 2 years of age. (Current Controlled Trials number, ISRCTN48656428.)
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Preterm birth is a major risk factor for neurosensory impairments and disabil-ities, including cerebral palsy.1,2 A single 
course of antenatal corticosteroids given to wom-
en at risk for preterm delivery substantially reduces 
the risk of neonatal mortality and morbidity and 
reduces the risk of long-term neurologic sequelae.3 
However, in comparison with unexposed infants, 
infants born more than 7 days after exposure to 
a single course of antenatal corticosteroids have 
lower birth weight3 and increased perinatal mor-
tality.4 It therefore became common clinical prac-
tice to repeat the dose of antenatal corticosteroids 
after 7 or more days, despite a lack of evidence to 
support this practice.5 However, current guidelines 
do not support the use of repeat doses of ante-
natal corticosteroids outside of clinical trials.6
Lambs exposed to repeat doses of antenatal 
corticosteroids have higher blood pressure,7 re-
duced skeletal growth,7 delayed neuronal myelin-
ation,8 and lower brain weight in later life9 than 
lambs exposed to a single dose. In observational 
studies in humans, exposure to repeat courses of 
corticosteroids has been associated with poorer 
infant growth,10 abnormal childhood behavior,11 
and delayed psychomotor development12 as com-
pared with exposure to a single course. However, 
not all observational studies have shown an in-
creased incidence of neurosensory disability in 
childhood after repeat doses of corticosteroids,10,13 
and one study suggested a reduction in the inci-
dence of cerebral palsy.11
We previously reported short-term results of 
the Australasian Collaborative Trial of Repeat 
Doses of Steroids (ACTORDS), in which babies 
of women randomly assigned to repeat doses of 
corticosteroids as compared with babies of wom-
en assigned to a single course, were much less 
likely to have respiratory distress syndrome (33% 
vs. 41%, P = 0.01), severe neonatal lung disease (12% 
vs. 20%, P<0.001), and serious neonatal morbidity 
(20% vs. 26%, P = 0.02).14 However, z scores for 
weight and head circumference were lower at birth 
in the repeat-dose group, although there were no 
significant differences by the time of hospital 
discharge.
A meta-analysis of the currently available evi-
dence from randomized, controlled trials of wom-
en given repeat doses of antenatal corticosteroids 
similarly showed a reduction in the risk of neo-
natal respiratory distress syndrome as compared 
with those given a single course (26% vs. 32%; 
relative risk, 0.82; 95% confidence interval [CI], 
0.72 to 0.93; four trials, 2155 women).15 We are 
unaware of any reports from randomized clinical 
trials on developmental and health outcomes in 
later childhood after exposure to repeat doses of 
antenatal corticosteroids.
We assessed outcomes at 2 years of corrected 
age of surviving children whose mothers took 
part in the ACTORDS trial. We aimed to deter-
mine whether exposure to repeat doses of ante-
natal corticosteroids affected the rate of survival 
free of major neurosensory disability (caused by 
impairments such as cerebral palsy, blindness, 
deafness, or developmental delay); body size; gen-
eral health, including respiratory health; blood 
pressure; or behavior.
Me thods
Design and Study Population
Eligible children were born to women recruited 
into the ACTORDS trial and were discharged 
home alive. As previously reported,14 women were 
eligible for the trial if they were considered by 
their obstetricians to be at risk for preterm deliv-
ery at less than 32 weeks of gestation with a 
single, twin, or triplet pregnancy and had received 
an initial course of a corticosteroid 7 or more 
days earlier. The research and ethics committees 
at the 23 collaborating hospitals approved the 
protocol.
Intervention
Women who gave written informed consent that 
included follow-up of their children through 
2 years of corrected age were randomly assigned 
to the repeat-corticosteroid group or the placebo 
group and given an intramuscular injection of ei-
ther betamethasone (11.4 mg of Celestone Chrono-
dose, Schering-Plough) or saline placebo; the dose 
was repeated weekly if the woman remained at 
risk for preterm delivery before 32 weeks of gesta-
tion. Randomization was performed by a central 
telephone randomization service with stratifica-
tion according to center, gestational age, and num-
ber of fetuses.14
Two-Year Follow-Up
Contact with mothers of infants discharged home 
alive was maintained at 6, 12, and 18 months 
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after birth. Surviving children were assessed at 
2 years of corrected age by a developmental pedia-
trician and a psychologist, with staff and families 
unaware of treatment-group assignment. The pedi-
atric assessment included measurement of weight, 
height, head circumference, and blood pressure; 
assessment of vision and hearing; and a neuro-
logic examination. Body-size measurements were 
converted to z scores (standard-deviation scores) 
specific for age and sex.16 Blood pressure was mea-
sured according to local practice, and measure-
ments were converted to z scores specific for age, 
height, and sex, with hypertension defined as sys-
tolic or diastolic blood pressure above the 95th 
percentile.17 Children were considered blind if 
vision in both eyes was worse than 6/60. Children 
were considered deaf if they required hearing aids. 
The criteria for cerebral palsy included abnormali-
ties of muscle tone as well as loss of motor func-
tion.18
The psychological assessment included the Psy-
chomotor Developmental Index and the Mental 
Developmental Index of the Bayley Scales of In-
fant Development19 or an equivalent psychologi-
cal test. Both indexes of the Bayley Scales have 
a mean (±SD) score of 100±15, and higher scores 
indicate better performance. Children unable to 
complete the Psychomotor Developmental Index 
or the Mental Developmental Index because of 
severe psychomotor or developmental delay were 
assigned scores of 49.
Severe neurosensory disability was defined as 
severe cerebral palsy (the child was considered 
permanently nonambulant), severe developmental 
delay (Mental Developmental Index score, >3 SD 
below the mean), or blindness. Moderate disabil-
ity was defined as moderate cerebral palsy (the 
child was nonambulant at 2 years of age but was 
likely to walk), moderate developmental delay 
(Mental Developmental Index score, >2 SD to 3 SD 
below the mean), or deafness. Mild disability was 
defined as either mild cerebral palsy (the child 
was able to walk by 2 years of age) or mild de-
velopmental delay (Mental Developmental Index 
score, >1 SD to 2 SD below the mean).
Each child’s parent or caregiver completed a 
questionnaire on the child’s history of illness, 
including respiratory illness, and the use of health 
services since the primary hospitalization. Each 
parent or caregiver also completed the Child 
Behavior Checklist, a rating scale that screens for 
behavioral and emotional problems.20
Outcome Variables
Primary Outcomes
The primary prespecified outcome was survival at 
the corrected age of 2 years free of major neuro-
sensory disability, defined as survival free of 
moderate or severe disability. The other primary 
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Figure 1. Randomization, Treatment, and 2-Year Follow-up of Participants.
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Table 1. Characteristics of the Women and Their Infants.*
Characteristic
Repeat-Corticosteroid  
Group
(N=464)
Placebo  
Group
(N=460) P Value
Maternal age — yr 30.0±6.0 29.9±5.9 0.84
Parity — no. (%) 0.69
0 146 (31.5) 146 (31.7)
1, 2, or 3 275 (59.3) 264 (57.4)
≥4 43 (9.3) 50 (10.9)
Smoking during pregnancy — no. (%) 153 (33.0) 152 (33.0) 0.98
Gestational age at study entry — wk 0.71
Median 28.6 28.6
Interquartile range 26.4–30.3 26.4–30.1
Gestational age at initial dose of corticosteroids — wk 0.85
Median 26.8 26.9
Interquartile range 24.7–28.7 24.9–28.7
Multiple pregnancy — no. (%)† 72 (15.5) 76 (16.5) 0.68
Previous preterm delivery <32 wk — no. (%) 47 (10.1) 47 (10.2) 0.96
Previous perinatal death ≥20 wk — no. (%) 40 (8.6) 41 (8.9) 0.88
Main reason for risk of preterm delivery — no. (%)
Antepartum hemorrhage 150 (32.3) 123 (26.7) 0.06
Preterm prelabor rupture of membranes 138 (29.7) 162 (35.2) 0.08
Preterm labor 126 (27.2) 117 (25.4) 0.55
Cervical incompetence 56 (12.1) 42 (9.1) 0.15
Preeclampsia or eclampsia 46 (9.9) 47 (10.2) 0.88
Severe growth restriction 35 (7.5) 29 (6.3) 0.46
Multiple pregnancy† 31 (6.7) 23 (5.0) 0.28
Other 36 (7.8) 48 (10.4) 0.16
Highest level of maternal education —  
no./total no. (%)
0.86
Secondary 247/460 (53.7) 241/456 (52.9)
Tertiary 216/460 (47.0) 206/456 (45.2)
No. of doses of treatment given — no. (%) 0.10
0 4 (0.9) 7 (1.5)
1 185 (39.9) 195 (42.4)
2 or 3 155 (33.4) 169 (36.7)
≥4 120 (25.9) 89 (19.3)
Sex of child — no. (%)‡ 0.61
Male 295 (55.6) 289 (53.8)
Female 236 (44.4) 248 (46.2)
Gestational age at birth — wk‡ 32.8±3.9 32.6±3.8 0.58
Birth weight — g‡ 1911±823 1915±803 0.97
* Plus–minus values are means ±SD.
† Multiple pregnancies are twins or triplets.
‡ Data are based on 531 infants in the repeat-corticosteroid group and 537 in the placebo group.
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outcome was body size (weight, height, and head 
circumference).
Secondary Outcomes
The secondary outcomes were general health, in-
cluding the use of health services since primary 
discharge; hospital readmission; respiratory mor-
bidity, defined as the need for hospital admission 
for respiratory illness and the rate of asthma (de-
termined on the basis of parental report of recur-
rent cough and wheeze requiring treatment with 
a bronchodilator); blood-pressure z scores and pro-
portions in the hypertensive range; child behav-
ior assessed by the Child Behavior Checklist20; 
incidence of neurosensory impairments and dis-
abilities; total number of deaths by 2 years of cor-
rected age, including stillbirths, neonatal deaths, 
and deaths after hospital discharge; and the 
combined adverse outcome of death or any neu-
rosensory disability at 2 years of corrected age.
Statistical Analysis
We originally estimated that 918 children who were 
alive at 2 years of corrected age would be available 
for assessment. A trial with 524 babies in the re-
peat-corticosteroid group and 536 babies in the pla-
cebo group, on the assumption of a design effect of 
1.2 to account for the clustering effect due to mul-
tiple gestations, has an 80% power to detect a sig-
nificant difference at an alpha level of 0.05 (two-
tailed) if survival free of major disability changed 
from 81% up to 88% or down to 73%. For measures 
of body size, this sample size would detect a change 
in z score of 0.2 SD with 80% power.
Statistical analyses were performed on an inten-
tion-to-treat basis with SAS software, version 9.1. 
All analyses were adjusted for gestational age at 
trial entry, antepartum hemorrhage, and preterm 
prelabor rupture of the membranes.14 Binary out-
comes are presented as relative risks with 95% 
confidence intervals. Relative risks were calculated 
with the use of log binomial regression.21 Con-
tinuous variables, if normally distributed, were 
analyzed by analysis of variance, with transforma-
tion of skewed data to normality before analysis. 
Robust variance estimation was used to account 
for clustering effects due to multiple gestations. 
A P value of less than 0.05 was considered to in-
dicate statistical significance. All P values were 
two-sided.
Table 2. Primary Outcomes, Assessed at 2 Years of Corrected Age.*
Outcome
Repeat-Corticosteroid 
Group (N = 524)
Placebo Group
(N = 536)
Adjusted Relative Risk
(95% CI)†
Adjusted 
P Value
Survival free of major neurosensory  
disability — no. (%)‡
442 (84.4) 434 (81.0) 1.04 (0.98 to 1.10) 0.20
Adjusted Mean Difference  
(95% CI)
Body-size measurements§
Weight — kg 12.6±1.9 12.6±1.9 −0.1 (−0.3 to 0.2) 0.62
Height — cm 87.6±4.6 87.7±4.7 −0.2 (−0.8 to 0.4) 0.45
Head circumference — cm 48.9±1.7 48.9±1.8 0.03 (−0.19 to 0.26) 0.78
z score
Weight −0.04±1.30 −0.01±1.29 −0.04 (−0.20 to 0.12) 0.62
Height 0.01±1.17 0.08±1.24 −0.08 (−0.23 to 0.08) 0.33
Head circumference −0.74±1.26 −0.76±1.33 0.002 (−0.162 to 0.167) 0.98
* Plus–minus values are means ±SD.
† Relative risks and mean differences were adjusted for gestational age, antepartum hemorrhage requiring hospitalization, 
and preterm prelabor rupture of the membranes at trial entry. Analyses of data for children are adjusted for clustering 
effects due to multiple gestations.
‡ This outcome is defined as being ambulant by 2 years of age and not having blindness, deafness, a developmental index 
score of more than 2 SD below the mean, or cerebral palsy.1
§ Body-size measurements are based on 520 children in the repeat-corticosteroid group and 527 in the placebo group.
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Table 3. Secondary Outcomes, Assessed at 2 Years of Corrected Age.*
Outcome
Repeat- 
Corticosteroid  
Group
(N = 568)
Placebo Group
(N = 578)
Adjusted  
Relative Risk  
(95% CI)†
Adjusted Mean  
Difference  
(95% CI)
Adjusted  
P Value
Death — no. (%) 29 (5.1) 32 (5.5) 0.91 (0.55 to 1.53) 0.73
Death or any neurosensory disability  
— no./total no. (%)
204/524 (38.9) 214/536 (39.9) 1.00 (0.85 to 1.17) 1.00
Death or moderate-to-severe disability 82/524 (15.6) 102/536 (19.0) 0.85 (0.64 to 1.12) 0.25
Death or severe disability 52/524 (9.9) 61/536 (11.4) 0.89 (0.62 to 1.29) 0.54
Cerebral palsy — no./total no. (%) 
Any 22/521 (4.2) 25/526 (4.8) 0.91 (0.51 to 1.63) 0.74
None 499/521 (95.8) 501/526 (95.2) 1.00 (0.98 to 1.03) 0.73
Severity‡ 0.89
Mild 9/521 (1.7) 10/526 (1.9) 0.91 (0.38 to 2.22) 0.84
Moderate 7/521 (1.3) 10/526 (1.9) 0.71 (0.27 to 1.85) 0.48
Severe 6/521 (1.2) 5/526 (1.0) 1.24 (0.36 to 4.21) 0.73
Blindness — no./total no. (%) 3/521 (0.6) 1/526 (0.2) 2.94 (0.26 to 33.57) 0.39
Deafness — no./total no. (%) 4/521 (0.8) 5/526 (1.0) 0.77 (0.19 to 3.06) 0.71
Bayley PDI score§ 92.5±17.3 92.1±16.7 0.2 (−2.0 to 2.5) 0.83
Bayley MDI score¶ 91.1±17.1 90.5±17.7 0.1 (−2.2 to 2.4) 0.90
Delayed development — no./total no. (%)‖ 0.49
None 327/495 (66.1) 329/504 (65.3) 1.00 (0.91 to 1.11) 0.93
Mild 120/495 (24.2) 110/504 (21.8) 1.12 (0.88 to 1.42) 0.37
Moderate 25/495 (5.1) 36/504 (7.1) 0.72 (0.43 to 1.21) 0.21
Severe 23/495 (4.6) 29/504 (5.8) 0.84 (0.47 to 1.50) 0.56
Neurosensory disability — no./total no. (%)** 0.50
None 320/495 (64.6) 322/504 (63.9) 1.00 (0.91 to 1.11) 0.97
Mild 122/495 (24.6) 112/504 (22.2) 1.12 (0.89 to 1.43) 0.33
Moderate 30/495 (6.1) 41/504 (8.1) 0.75 (0.47 to 1.20) 0.23
Severe 23/495 (4.6) 29/504 (5.8) 0.84 (0.47 to 1.50) 0.56
Use of health services since discharge  
— no./total no. (%)
Hospital readmission 266/527 (50.5) 261/533 (49.0) 1.04 (0.92 to 1.18) 0.50
Physical therapy 28/521 (5.4) 21/526 (4.0) 1.35 (0.78 to 2.34) 0.29
Organized play group†† 32/521 (6.1) 43/526 (8.2) 0.73 (0.45 to 1.20) 0.21
Admission for respiratory illness 174/527 (33.0) 177/533 (33.2) 1.01 (0.84 to 1.20) 0.95
Asthma — no./total no. (%) 122/527 (23.1) 142/533 (26.6) 0.88 (0.71 to 1.09) 0.24
Systolic blood pressure — z score‡‡ 0.2±1.2 0.3±1.2 −0.1 (−0.2 to 0.1) 0.56
Diastolic blood pressure — z score§§ 1.1±0.9 1.0±1.0 0.01 (−0.15 to 0.16) 0.93
Hypertension — no./total no. (%)¶¶ 92/301 (30.6) 103/327 (31.5) 0.98 (0.77 to 1.25) 0.85
Weight — no./total no. (%)‖‖
<10th percentile 68/520 (13.1) 81/527 (15.4) 0.86 (0.63 to 1.18) 0.35
>90th percentile 70/520 (13.5) 70/527 (13.3) 1.01 (0.73 to 1.39) 0.97
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R esult s
Of the 982 women enrolled, 489 were assigned 
to the repeat-corticosteroid group and 493 to the 
placebo group (Fig. 1). Clinical outcomes up to 
the time of discharge after the primary hospital-
ization have been reported previously for all 982 
women who underwent randomization and their 
1146 fetuses who were alive at randomization.14
Of the 1090 infants discharged home alive, 
5 had died by 2 years of corrected age (2 in the 
repeat-corticosteroid group and 3 in the placebo 
group). Of the 1085 survivors, 1047 (96%) were 
assessed at 2 years of corrected age and 38 had 
no pediatric assessment (18 in the repeat-cortico-
steroid group and 20 in the placebo group) (Fig. 1). 
The maternal characteristics and the reasons for 
the risk of preterm delivery were similar in the two 
treatment groups (Table 1).
Primary Outcomes
The rates of survival free of major disability did not 
differ significantly between the repeat-cortico-
steroid and placebo groups (84.4% and 81.0%, 
respectively; adjusted relative risk, 1.04; 95% CI, 
0.98 to 1.10; adjusted P = 0.20) (Table 2). There were 
also no significant differences between the groups 
in measurements or z scores for weight, height, or 
head circumference (Table 2). In a prespecified 
analysis according to the number of repeat trial 
treatments given (one, two or three, or four or 
more treatments), there were no significant inter-
actions with the treatment effect for survival free 
of major disability or for measures of body size 
(unadjusted and adjusted P>0.25).
Secondary Outcomes
There were no significant differences between 
the groups in the use of health service resources. 
The overall rates of readmission to the hospital 
were similar, as were the rates of asthma and ad-
mission to the hospital with a respiratory illness. 
There were no significant differences between the 
groups in mean systolic or diastolic blood pres-
sures or in the proportions of children with blood 
pressure in the hypertensive range (Table 3). Chil-
dren exposed to one or more repeat doses of ante-
natal corticosteroids were not more likely to be 
small for their age in weight, height, or head cir-
cumference than children not exposed (Table 3).
Table 3. (Continued.)
Outcome
Repeat- 
Corticosteroid  
Group
(N = 568)
Placebo Group
(N = 578)
Adjusted  
Relative Risk  
(95% CI)†
Adjusted Mean  
Difference  
(95% CI)
Adjusted  
P Value
Height <10th percentile — no./total no. (%)‖‖ 60/520 (11.5) 68/520 (13.1) 0.92 (0.65 to 1.29) 0.62
Head circumference <10th percentile  
— no./total no. (%)‖‖
160/519 (30.8) 167/522 (32.0) 0.98 (0.81 to 1.18) 0.81
* Plus–minus values are means ±SD.
† Relative risks and mean differences were adjusted for gestational age, antepartum hemorrhage requiring hospitalization, and preterm 
prelabor rupture of the membranes at trial entry. Analyses of data for children are adjusted for clustering effects due to multiple gesta-
tions.
‡ The P value for the linear treatment effect is 0.85.
§ The values are based on 472 children in the repeat-corticosteroid group and 486 in the placebo group. PDI denotes Psychomotor 
Developmental Index.
¶ The values are based on 474 children in the repeat-corticosteroid group and 493 in the placebo group. MDI denotes Mental Devel-
opmental Index.
‖ A few children assessed with alternative psychometric tests are included. The P value for the linear treatment effect is 0.33.
** Severe neurosensory disability was defined as severe cerebral palsy (child considered permanently nonambulant), severe developmental 
delay (MDI score, >3 SD below the mean), or blindness. Moderate disability was defined as moderate cerebral palsy (child nonambulant 
at 2 years but likely to walk), moderate developmental delay (MDI score, >2 SD to 3 SD below the mean), or deafness. Mild disability was 
defined as either mild cerebral palsy (walking at 2 years) or mild developmental delay (MDI score, >1 SD to 2 SD below the mean). 
Children with no disability had no neurosensory impairment. The P value for the linear treatment effect is 0.35.
†† An organized play group is defined as a supervised group in which play is treatment oriented.
‡‡ The values are based on 327 children in the repeat-corticosteroid group and 345 in the placebo group.
§§ The values are based on 301 children in the repeat-corticosteroid group and 327 in the placebo group.
¶¶ Hypertension is defined as either systolic hypertension (systolic blood pressure >95th percentile) or diastolic hypertension (diastolic blood 
pressure >95th percentile).17
‖‖ Percentiles for weight, height, and head circumference are taken from a standard chart.16
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There were 61 deaths (5.3%): 29 (5.1%) in the 
repeat-corticosteroid group and 32 (5.5%) in the 
placebo group (Table 3). There were no signifi-
cant differences between the treatment groups in 
the distribution of the severity of neurosensory 
disability, in any of the individual neurosensory 
impairments (cerebral palsy, blindness, deafness, 
and developmental delay), or in the combined out-
come of death or any neurosensory disability (Ta-
ble 3). The mean Psychomotor Developmental 
and Mental Developmental Index scores did not 
significantly differ between treatment groups 
(Table 3).
For the Child Behavior Checklist, there were 
no significant differences between the groups in 
the total or individual mean scores for internal-
izing, externalizing, emotional reactivity, anxiety 
or depression, somatic complaints, withdrawal, 
sleep problems, attention problems, or aggressive 
behavior (Table 4). Similarly, there were no signif-
icant differences in the proportions of children 
with scores within the clinical range (the top 
2.5th percentile, indicating further assessment is 
warranted)20 in any of these behavioral domains, 
with the exception of attention problems, for 
which there were more children in the clinical 
Table 4. Child Behavior Checklist Scores at 2 Years of Corrected Age.*
Outcome
Repeat-Corticosteroid  
Group
(N = 519)
Placebo Group
(N = 526)
Adjusted Mean Difference  
(95% CI)†
Adjusted  
P Value
Child Behavior Checklist domain 
scores
Total 35.6±21.3 35.0±20.2 0.8 (−1.9 to 3.4) 0.56
Internalizing 8.3±6.4 8.0±6.5 0.3 (−0.6 to 1.1) 0.55
Externalizing 13.9±8.6 13.6±8.0 0.4 (−0.7 to 1.4) 0.51
Emotionally reactive 2.3±2.2 2.3±2.3 0.1 (−0.2 to 0.4) 0.65
Anxious or depressed 2.7±2.2 2.6±2.2 0.1 (−0.2 to 0.4) 0.51
Somatic complaints 1.8±2.1 1.8±2.0 0.1 (−0.2 to 0.3) 0.71
Withdrawn 1.5±1.8 1.4±1.8 0.1 (−0.2 to 0.3) 0.60
Sleep problems 2.9±2.8 3.1±2.8 −0.1 (−0.4 to 0.3) 0.66
Attention problems 2.6±2.1 2.4±1.9 0.2 (−0.1 to 0.4) 0.18
Aggressive behavior 11.3±7.0 11.2±6.8 0.2 (−0.7 to 1.1) 0.69
Adjusted Relative Risk 
(95% CI)†
Scores within clinical range — no. 
(%)‡
Total 68 (13.1) 63 (12.0) 1.11 (0.79 to 1.57) 0.54
Internalizing 46 (8.9) 51 (9.7) 0.94 (0.63 to 1.39) 0.76
Externalizing 57 (11.0) 51 (9.7) 1.18 (0.81 to 1.72) 0.40
Emotionally reactive 8 (1.5) 8 (1.5) 1.02 (0.40 to 2.63) 0.96
Anxious or depressed 7 (1.3) 9 (1.7) 0.82 (0.31 to 2.14) 0.68
Somatic complaints 23 (4.4) 21 (4.0) 1.12 (0.62 to 2.00) 0.71
Withdrawn 23 (4.4) 28 (5.3) 0.87 (0.50 to 1.50) 0.61
Sleep problems 25 (4.8) 29 (5.5) 0.87 (0.52 to 1.46) 0.59
Attention problems 31 (6.0) 17 (3.2) 1.87 (1.03 to 3.42) 0.04
Aggressive behavior 21 (4.0) 21 (4.0) 1.06 (0.57 to 1.98) 0.85
* Plus–minus values are means ±SD.
† Mean differences and relative risks were adjusted for gestational age, antepartum hemorrhage requiring hospitaliza-
tion, and preterm prelabor rupture of the membranes at trial entry. Analyses of data for children are adjusted for clus-
tering effects due to multiple gestations.
‡ Scores in the clinical range are those in the top 2.5th percentile, indicating that further assessment of the child is war-
ranted.
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range in the repeat-corticosteroid than in the 
placebo group (6.0% vs. 3.2%; adjusted relative 
risk, 1.87; 95% CI, 1.03 to 3.42; P = 0.04) (Table 4). 
In post hoc analyses, there were no significant 
interactions between sex and treatment effect on 
child behavior (unadjusted and adjusted P>0.18).
Discussion
In this follow-up study of offspring of women at 
risk for preterm delivery who were assigned to re-
peat doses of betamethasone or placebo, exposure 
to repeat doses of corticosteroids had no signifi-
cant effects on survival free of major neurosensory 
disability or on childhood growth to 2 years of 
corrected age. The study used central randomiza-
tion, the outcome assessors were unaware of treat-
ment-group assignment, the follow-up rate achieved 
was very high, and the sample size was sufficient-
ly large to detect important but small differences 
between treatment groups.
These results may be viewed as reassuring, 
given previous reports of adverse effects of repeat 
doses of corticosteroids on neuronal myelination8 
and brain weight in sheep,9 as well as the in-
creased rate of neurosensory disability in child-
hood reported in some observational studies of 
children whose mothers received repeat cortico-
steroid doses.12 The differences between the find-
ings in sheep and humans may be related to the 
much greater effects of repeat corticosteroids on 
fetal growth in sheep,7 perhaps due to the higher 
doses used, as well as differences in the timing 
of brain growth and myelination in the two spe-
cies.22 Our results are robust, in that they show a 
similar distribution of developmental outcomes 
in the corticosteroid and placebo groups across a 
range of different measures of neurosensory dis-
ability. However, since neurosensory abilities at 
2 years of age are of limited predictive value, par-
ticularly for more subtle problems, follow-up of 
these children is warranted later in childhood, 
when other important cognitive outcomes, such 
as executive function, can be determined more 
completely.
We also found no differences between treat-
ment groups in body-size measurements at 2 years. 
This is consistent with our earlier finding that 
there were no differences between the groups in 
body size at initial discharge from the hospital. 
The mean size at birth also did not differ signifi-
cantly between the groups, although the z scores 
for weight and head circumference at birth were 
slightly lower in infants who were exposed to 
repeat doses of corticosteroids.14 Together these 
findings suggest that any effects of repeat doses 
of corticosteroids on growth before birth are un-
likely to have any clinically important effect on 
size in later life. The reason for the difference be-
tween our findings and those of many studies in 
animals showing long-term impairment of growth 
after antenatal corticosteroids is not clear, but it 
may in part be related to the longer period of 
administration and larger doses of corticoste-
roids used in the studies in animals.7
Almost one third of the children in our study 
had blood pressures above the 95th percentile. 
Preterm birth is itself associated with increased 
blood pressure in adulthood23,24 and with a dou-
bling of the risk of hypertension by 30 years of 
age.25 However, we found no apparent effect of 
exposure to repeat corticosteroids on blood pres-
sure at 2 years of age. This is consistent with the 
findings of previous randomized trials that ex-
posure to a single course of antenatal corticoste-
roids has no effect on blood pressure in later 
childhood26 and early adulthood,27,28 but not with 
findings of observational studies23,29 and studies 
in animals suggesting that antenatal corticoste-
roid exposure increases blood pressure in both 
fetal30 and postnatal7,31 life. These differences 
may be related in part to the lack of effects on 
growth in our study, since in rats, exposure to 
antenatal corticosteroids does not alter blood pres-
sure unless growth is also affected.32 The differ-
ences may also be related to the timing of corti-
costeroid exposure, since fetuses exposed to repeat 
doses of corticosteroids, as was the case in our 
study, often are exposed to their first dose ear-
lier in gestation than those exposed to a single 
dose.33
Some studies in animals have suggested that 
the effects of antenatal corticosteroid exposure 
on blood pressure may increase with increasing 
postnatal age.34 Therefore, long-term follow-up 
of this and similar randomized trials will be im-
portant to determine whether repeat doses of 
antenatal corticosteroids have adverse effects on 
later cardiovascular health beyond those associ-
ated with preterm birth.
Overall child behavior was similar between the 
treatment groups. We did not find an increase in 
aggressive behavior in children who had been ex-
posed to repeat doses of corticosteroids, as was 
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reported in an earlier observational study.11 The 
higher proportion of children exposed to repeat 
doses of corticosteroids who reached the clinical 
range of scores for attention problems may have 
been a chance finding, since it represents a dif-
ference in the sum of 5 items in a 100-item 
standardized test. However, further follow-up is 
warranted, given the reported changes in neuro-
transmitter systems and associated increases in 
hyperactivity and anxiety-like behavior in animals 
after antenatal exposure to repeat doses of corti-
costeroids.35,36
Our results should not be generalized to other 
treatment regimens or inclusion criteria. A trial 
using a single rescue or booster dose of cortico-
steroid when preterm birth was imminent (with-
in 48 hours) did not show benefit in the neonatal 
period.37 The 2-to-3-year follow-up of children in 
the National Institute of Child Health and Human 
Development Maternal–Fetal Medicine Units Net-
work trial38 reported in this issue of the Journal39 
showed no significant differences in physical or 
neurocognitive measures between children who 
had been exposed to repeat courses of antenatal 
corticosteroids and those who had been exposed 
to single courses. Another trial of repeat ante-
natal corticosteroids has completed recruitment, 
and the results are awaited.40
Exposure to one or more repeat doses of ante-
natal betamethasone has previously been shown 
to reduce the risk of respiratory distress syndrome 
and overall serious neonatal morbidity.14,15 The 
current report shows that this treatment does not 
change survival free of major neurosensory dis-
ability or growth to 2 years of age. On the basis 
of this evidence, clinicians may wish to consider 
the use of a single injection of Celestone Chrono-
dose, or equivalent, repeated weekly if the woman 
remains at risk for very preterm delivery, 7 or more 
days after an initial course of antenatal cortico-
steroids.
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APPENDIX
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Caboolture Hospital, Queensland, Australia (3) — M. Ratnapala, A. Hanafy; Christchurch Women’s Hospital, New Zealand (34) — R. 
Reid, N. Austin, B. Darlow,* J. Hunter, H. Liley, N. Mogridge, D. Poad; Dunedin Hospital, New Zealand (16) — R. Broadbent,* K. Gillies, 
F. Patel, S. Tout, D. Wilson; Hervey Bay Hospital, Queensland, Australia (8) — D. Ludwig,* G. Carman, K. Ende, J. Heininger, F. Tan, 
J. Van der Westhuyzen; John Hunter Hospital, New South Wales, Australia (10) — W. Giles, A. Gill,* L. Miljkovic, A. Nicoll, S. 
O’Callaghan, A. Vimpani; Mater Mothers’ Hospital, Brisbane, Queensland, Australia (86) — F. Chan (deceased), V. Flenady, R. Cincotta, P. 
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Hospital, New Zealand (26) — L. Mildenhall,* I. Brown, L. Hayward, D.W. Smith, A. Thesing, S. Wadsworth; Monash Medical Centre, 
Victoria, Australia (30) — R. Burrows, E. Carse, M. Charlton, M. Hayes, N. Taylor, V. Yu*; National Women’s Hospital, New Zealand 
(156) — L. McCowan, R. Taylor, J. Harding,* C. Bevan, S. Aftimos, J. Alsweiler, D. Armstrong, M. Battin, J.A. Dezoete, M. Light, P. 
Stone, A. Thesing, N. Webster, C. West, C. Kuschel; Palmerston North Hospital, New Zealand (1) — K. Gillies, G. Bates, D. Baillie, L. 
Hastings, A. Jory, P. Mercer, R. Pullen, G. Scott; Royal Hobart Hospital, Tasmania, Australia (13) — G. Bury, S. Bacic, K. Butterley, 
H. Giannaros, S. Jarrell, G. Standen; Royal Hospital for Women, New South Wales, Australia (8) — C. Fisher, D. Challis, K. Asgill, R. 
Buist, D. Cameron, K. Dyer, K. Lui, S. Milner, L. Sutton, L. Woodhart; Royal North Shore Hospital, New South Wales, Australia (28) — J. 
Morris, J. Bowen, V. Gallimore, F. Gibson, G. Leslie, C. Maher; Royal Prince Alfred Women’s & Babies Hospital, New South Wales, 
Australia (7) — A. Child, D. Henderson-Smart, H. Jeffery, R. Ogle, D. Osborn, B. Peat, H. Phipps, J. Polverino, I. Rieger, J. Vaughan, 
C. Wocadlo; Royal Brisbane and Women’s Hospital, Queensland, Australia (104) — P. Colditz,* R. Allen, T. de Dassel, T. Fitzsimmons, 
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Mercy Hospital for Women, Victoria, Australia (56) — A. Watkins; S. Fraser,* P. Wein, J. Higgins, E. Kelly, J. Keng, E. McCarthy, A. 
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A. Haslam, C. Holmes, R. McLaughlin, N. Meher-Homji, J. Reetz, P. Weston; Wellington Women’s Hospital, New Zealand (24) — M. 
Sangalli, N. Bedford, S. Calvert, C. Coles, G. Corbett, D. Elder, U. Preston, V. Richardson; Women’s and Children’s Hospital, South 
Australia, Australia (174) — C. Crowther, P. Ashwood, C. Barnett, V. Bhatia, V. Coppinger, A. Deussen, J. Dodd, J. Fitzgerald, S. Gib-
bons, E. Griffith, K. Harris, R. Haslam,* B. Headley, J. Hiller, C. Holst, T.Y. Khong, E. Lioulios, K. McLaughlin, A. McPhee, M. 
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